A310 helical turn is essential for the proliferation-inhibiting properties of macrophage inflammatory protein-1 alpha (CCL3)

Blood

Volumn 107, Issue 4, 2006, Pages 1284-1291

  Ottersbach, Katrin ^a   Mclean, John ^a   Isaacs, Neil W ^a   Graham, Gerard J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYSTEINE DERIVATIVE; DIPEPTIDE DERIVATIVE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; BETA CHEMOKINE; CCL5 PROTEIN, HUMAN; MACROPHAGE INFLAMMATORY PROTEIN 1; PRIMER DNA; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; EMBRYO; GENE CONSTRUCT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKOCYTE MIGRATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; AMINO ACID SEQUENCE; ANIMAL; CELL DIVISION; CHEMISTRY; CLONOGENIC ASSAY; CYTOLOGY; GENETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; PROTEIN SECONDARY STRUCTURE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL DIVISION; CHEMOKINES, CC; COLONY-FORMING UNITS ASSAY; DNA PRIMERS; HEMATOPOIETIC STEM CELLS; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MICE; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY; RANTES; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 32644446322     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-3112     Document Type: Article

References (53)

1. Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev Biol. 2001;17:387-403.
2. Youn BS, Mantel C, Broxmeyer HE. Chemokines, chemokine receptors and hematopoiesis. Immunol Rev. 2000;177:150-174.
3. Broxmeyer HE, Youn BS, Kim C, Hangoc G, Cooper S, Mantel C. Chemokine regulation of hematopoiesis and the involvement of pertussis toxin-sensitive G alpha i proteins. Ann N Y Acad Sci. 2001;938:117-127; discussion 127-118.
4. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004;22:891-928.
5. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today. 1999;20:254-257.
6. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
7. Doitsidou M, Reichman-Fried M, Stebler J, et al. Guidance of primordial germ cell migration by the chemokine SDF-1. Cell. 2002;111:647-659.
8. Knaut H, Werz C, Geisler R, Nusslein-Volhard C. A zebrafish homologue of the chemokine receptor Cxcr4 is a germ-cell guidance receptor. Nature. 2003;421:279-282.
9. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology, XXII: nomenclature for chemokine receptors. Pharmacol Rev. 2000;52:145-176.
10. Nibbs R, Graham G, Rot A. Chemokines on the move: control by the chemokine "interceptors" Duffy blood group antigen and D6. Semin Immunol. 2003;15:287-294.
11. Jamieson T, Cook, D, Nibbs RJB, et al. The chemokine receptor D6 limits the inflammatory response in vivo. Nature Immunology. 2005;6:403-411.
12. Graham GJ. Growth inhibitors in haemopoiesis and leukaemogenesis. Baillieres Clin Haematol. 1997;10:539-559.
13. Broxmeyer HE, Kim CH, Cooper SH, Hangoc G, Hromas R, Pelus LM. Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Ann N Y Acad Sci. 1999;872:142-162.
14. Graham GJ, Pragnell IB. SCI/MIP-1 alpha: a potent stem cell inhibitor with potential roles in development. Dev Biol. 1992;151:377-381.
15. Graham GJ, Wilkinson PC, Nibbs RJ, et al. Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP-1alpha by mutagenesis of the proteoglycan binding site. EMBO J. 1996;15:6506-6515.
16. Graham GJ, Wright EG, Hewick R, et al. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature. 1990;344:442-444.
17. Broxmeyer HE, Sherry B, Lu L, et al. Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood. 1990;76:1110-1116.
18. Lord BI, Marshall E, Woolford LB, Hunter MG. BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation. Br J Cancer. 1996;74:1017-1022.
19. Dunlop DJ, Wright EG, Lorimore S, et al. Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo. Blood. 1992;79:2221-2225.
20. Cooper S, Mantel C, Broxmeyer HE. Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha. Exp Hematol. 1994;22:186-193.
21. Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci U S A. 1993;90:7158-7162.
22. Proudfoot AE, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A. 2003;100:1885-1890.
23. Burns JM, Gallo RC, DeVico AL, Lewis GK. A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. J Exp Med. 1998;188:1917-1927.
24. Ottersbach K, Graham GJ. Aggregation-independent modulation of proteoglycan binding by neutralization of C-terminal acidic residues in the chemokine macrophage inflammatory protein 1alpha. Biochem J. 2001;354:447-453.
25. Weber M, Uguccioni M, Baggiolini M, Clark-Lewis I, Dahinden CA. Deletion of the NH2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant. J Exp Med. 1996;183:681-685.
26. Lambeir AM, Proost P, Durinx C, et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem. 2001;276:29839-29845.
27. Proost P, Mahieu F, Schutyser E, Van Damme J. Posttranslational processing of chemokines. Methods Mol Biol. 2004;239:27-44.
28. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood. 2000;96:1674-1680.
29. Nibbs RJ, Yang J, Landau NR, Mao JH, Graham GJ. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem. 1999;274:17478-17483.
30. Miyakawa T, Obaru K, Maeda K, Harada S, Mitsuya H. Identification of amino acid residues critical for LD78beta, a variant of human macrophage inflammatory protein-1alpha, binding to CCR5 and inhibition of R5 human immunodeficiency virus type 1 replication. J Biol Chem. 2002;277:4649-4655.
31. Ottersbach K, Cook DN, Kuziel WA, et al. Macrophage inflammatory protein-1alpha uses a novel receptor for primitive hematopoietic cell inhibition. Blood. 2001;98:3476-3478.
32. Lodi PJ, Garrett DS, Kuszewski J, et al. High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. Science. 1994;263:1762-1767.
33. Crump MP, Rajarathnam K, Kim KS, Clark-Lewis I, Sykes BD. Solution structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic inflammation. J Biol Chem. 1998;273:22471-22479.
34. Kuloglu ES, McCaslin DR, Kitabwalla M, Pauza CD, Markley JL, Volkman BF. Monomeric solution structure of the prototypical "C" chemokine lymphotactin. Biochemistry. 2001;40:12486-12496.
35. Perez-Canadillas JM, Zaballos A, Gutierrez J, et al. NMR solution structure of murine CCL20/MIP-3alpha, a chemokine that specifically chemoattracts immature dendritic cells and lymphocytes through its highly specific interaction with the beta-chemokine receptor CCR6. J Biol Chem. 2001;276:28372-28379.
36. Ye J, Mayer KL, Mayer MR, Stone MJ. NMR solution structure and backbone dynamics of the CC chemokine eotaxin-3. Biochemistry. 2001;40:7820-7831.
37. Zhang X, Chen L, Bancroft DP, Lai CK, Maione TE. Crystal structure of recombinant human platelet factor 4. Biochemistry. 1994;33:8361-8366.
38. Graham GJ, MacKenzie J, Lowe S, et al. Aggregation of the chemokine MIP-1 alpha is a dynamic and reversible phenomenon: biochemical and biological analyses. J Biol Chem. 1994;269:4974-4978.
39. Paolini JF, Willard D, Consler T, Luther M, Krangel MS. The chemokines Il-8, monocyte chemoattractant protein-1, and I-309 are monomers at physiologically relevant concentrations. J Immunol. 1994;153:2704-2717.
40. Graham GJ, Pragnell IB. Treating cancer: the potential role of stem cell inhibitors. Eur J Cancer. 1991;27:952-953.
41. Graham GJ, Freshney MG. CFU-A assay for measurement of the antiproliferative effects of chemokines on murine early hematopoietic progenitors. Methods Mol Biol. 2000;138:179-189.
42. Eckmann L, Freshney M, Wright EG, Sproul A, Wilkie N, Pragnell IB. A novel in vitro assay for murine haematopoietic stem cells. Br J Cancer Suppl. 1988;9:36-40.
43. Pragnell IB, Wright EG, Lorimore SA, et al. The effect of stem cell proliferation regulators demonstrated with an in vitro assay. Blood. 1988;72:196-201.
44. Lorimore SA, Pragnell IB, Eckmann L, Wright EG. Synergistic interactions allow colony formation in vitro by murine haemopoietic stem cells. Leuk Res. 1990;14:481-489.
45. Skelton NJ, Aspiras F, Ogez J, Schall TJ. Proton Nmr assignments and solution conformation of Rantes, a chemokine of the C-C type. Biochemistry. 1995;34:5329-5342.
46. MacLean JKF. Crystallographic studies on macrophage inflammatory protein-1α. 1997 PhD thesis, University of Glasgow.
47. Townson JR, Graham GJ, Landau NR, Rasala B, Nibbs RJ. Aminooxypentane addition to the chemokine macrophage inflammatory protein-1alpha P increases receptor affinities and HIV inhibition. J Biol Chem. 2000;275:39254-39261.
48. Graham GJ, Zhou L, Weatherbee JA, et al. Characterization of a receptor for macrophage inflammatory protein 1 alpha and related proteins on human and murine cells. Cell Growth Differ. 1993;4:137-146.
49. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med. 1997;186:1865-1872.
50. Mayer MR, Stone MJ. Identification of receptor binding and activation determinants in the N-terminal and N-loop regions of the CC chemokine eotaxin. J Biol Chem. 2001;276:13911-13916.
51. Bondue A, Jao SC, Blanpain C, Parmentier M, LiWang PJ. Characterization of the role of the N-loop of MIP-1 beta in CCR5 binding. Biochemistry. 2002;41:13548-13555.
52. Lecomte-Raclet L, Rholam M, Alemany M, et al. Dual structural requirements for multilineage hematopoietic-suppressive activity of chemokine-derived peptides. Biochemistry. 2000;39:9612-9622.
53. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med. 2003;197:1537-1549.